BOSTON--(BUSINESS WIRE)--Today, Thimble Point Acquisition Corp, Inc. (NASDAQ: THMA) (“Thimble Point”), a special purpose acquisition company, Pear Therapeutics, Inc. (“Pear”), the leader in developing ...

Upon Closing, the Combined Company will trade on the NASDAQ under the ticker symbol “PEAR” BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (“Pear”), the leader in developing and commercializing ...

Pear Therapeutics, a developer of prescription digital therapeutics, has agreed to go public via a merger with Thimble Point Acquisition Corp, a blank check company whose management team is associated ...

Based on reported first half revenues and a preliminary review of third quarter revenue, Pear reaffirms its 2021 guidance of $4.0 million in revenue If the proposals at the Special Meeting are ...